<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11206">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02961062</url>
  </required_header>
  <id_info>
    <org_study_id>CSAF312X2201</org_study_id>
    <nct_id>NCT02961062</nct_id>
  </id_info>
  <brief_title>Study of SAF312 as an Eye Drop for Treatment of Eye Pain Following Photorefractive Keratectomy (PRK) Surgery</brief_title>
  <official_title>A Randomized, Vehicle-controlled, Subject and Investigator-masked, Proof-of-concept Study to Evaluate the Use of Topical Ocular SAF312 in the Treatment of Postoperative Ocular Pain in Patients Undergoing Photorefractive Keratectomy (PRK) Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if SAF312 eye drops have an adequate safety and
      efficacy profile to justify further clinical development for the treatment of ocular pain
      associated with corneal epithelial defect such as after photorefractive keratectomy (PRK)
      surgery
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual analog scale (VAS) pre-dose pain assessment</measure>
    <time_frame>6 hours post-operatively</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average ocular pain VAS assessments</measure>
    <time_frame>From the first post-operative assessment to pre-dose 12 hours post-operative assesment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of and amount of rescue oral analgesics</measure>
    <time_frame>12, 24, 48 and 72 hours post-operatievly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS pain assessments</measure>
    <time_frame>The first 72 hours post-operatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of SAF312</measure>
    <time_frame>The first 72 hours post-operatively</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Postoperative Ocular Pain After PRK Surgery</condition>
  <arm_group>
    <arm_group_label>Treatment Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAF312</intervention_name>
    <arm_group_label>Treatment Sequence 1</arm_group_label>
    <arm_group_label>Treatment Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Treatment Sequence 1</arm_group_label>
    <arm_group_label>Treatment Sequence 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal eye exam except for refractive error at baseline.

          -  Myopia should not exceed -4.00 Diopters (sphere) and 3.00 diopters of astigmatism,
             with spherical equivalent not higher than -4.50, confirmed by manifest refraction at
             baseline.

        Exclusion Criteria:

          -  Monocular patient (including amblyopia) or best corrected visual acuity score worse
             than 20/80 (Snellen) or 55 letters (EDTRS), at baseline.

          -  Any systemic or ocular disease that might affect wound healing (such as severe
             rheumatoid arthritis or diabetes or history of keloid formation) or a history of
             ocular trauma, uveitis, infection, or inflammation in the 6 months prior to baseline.

          -  Previous refractive or corneal surgery (such as LASIK, PRK, radial keratotomy,
             pterygium removal, corneal transplantation).

          -  Chronic pain of any etiology or any significant illness which has not resolved within
             two (2) weeks prior to initial dosing.

        Other inclusion and exclusion criteria apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 8, 2016</lastchanged_date>
  <firstreceived_date>November 8, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ocular pain</keyword>
  <keyword>photorefractive keratectomy (PRK)</keyword>
  <keyword>SAF312</keyword>
  <keyword>corneal epithelial defect</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Eye Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
